To learn about the safety and tolerability of study drug combinations in patients with relapsed/refractory, IDH1-mutated myeloid malignancies with a co-signali…

Targeted TherapyIDH1-Mutated MalignanciesMutations

~Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT07032727

Phase 1

A Phase 1, Multicenter, Open-Label, Safety and Pharmacokinetic Study of Orally Administered Ivosidenib in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment

The objective of this study is to investigate the PK, PD, safety, and tolerability of ivosidenib in adult participants with IDH1-mutated malignancies and hepat…

IDH1-Mutated Malignancies

~Estimated

~$10 – $8,750

Servier Bio-Innovation LLCNCT07006688